KOPECKA, Joanna
KOPECKA, Joanna
ONCOLOGIA
Cardiac glycosides as new modulators of cholesterol metabolism
2012-01-01 I. Campia; V. Sala; J. Kopecka; C. Leo; N. Mitro; C. Costamagna; D. Caruso; G. Pescarmona;T. Crepaldi; D. Ghigo; A. Bosia; C. Riganti
Cardiac glycosides modulate cholesterol metabolism via SREBP-2 and LXR activation
2013-01-01 I. Campia; V. Sala; J. Kopecka; C. Leo; N. Mitro; C. Costamagna; D. Caruso; G. Pescarmona;T. Crepaldi; D. Ghigo; A. Bosia; C. Riganti
Cardioactive glycosides induce the efflux of cholesterol by upregulating ABCA1
2012-01-01 I. Campia; J. Kopecka ;G. Pescarmona; D. Ghigo ; C. Riganti
Digoxin and oubain increase the synthesis of cholesterol in human liver cells
2011-01-01 Joanna Kopecka; Ivana Campia; Amalia Bosia; Chiara Riganti
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target
2016-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, Fr; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
Liposomal doxorubicin reverses drug-resistance by inhibiting P-glycoprotein in human cancer cells
2010-01-01 I. Campia; C. Riganti; C. Voena; J. Kopecka; E. Enrico; C. Costamagna; D. Ghigo; A. Bosia
Mechanisms of Vgamma9Vdelta2 T cell activation by soluble metabolites generated by the mevalonate pathway.
2014-01-01 P. Sciancalepore; B. Castella; J. Kopecka; I. Campia; G. Gelsomino; M. Foglietta; D. Ghigo; M. Boccadoro; C. Riganti; M. Massaia.
Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity
2011-01-01 M. Polimeni; C. Voena; J. Kopecka; C. Riganti; G. Pescarmona; A. Bosia; D. Ghigo
Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity
2011-01-01 Manuela Polimeni; Claudia Voena; Johanna Kopecka; Chiara Riganti; Gianpiero Pescarmona; Amalia Bosia; Dario Ghigo
Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity
2011-01-01 M. Polimeni; C. Voena; J. Kopecka; C. Riganti; G. Pescarmona; A. Bosia; D. Ghigo
Nitrooxy-doxorubicin: A New Weapon Against Multidrug Resistance.
2013-01-01 Joanna Kopecka; Chiara Riganti; Barbara Rolando; Ivana Campia; Konstantin Chegaev; Loretta Lazzarato; Antonella Federico; Roberta Fruttero; Dario Ghigo
Pleiotropic effects of liposomal nanoparticles on ABCB1 in cancer cells
2012-01-01 I. Campia ; J.Kopecka; M.L. Pinzon; D. Ghigo; C. Riganti
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
2018-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Salvetti, C; Bomben, R; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Omede, P; Bonello, L; Kodipad, AA; Laurenti, L; Del Poeta, G; Mauro, FR; Bernardi, R; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
2016-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Laurenti, L; Zallio, F; Marchetti, M; Ruggeri, M; Omede, P; Ferretti, A; Del Poeta, G; Mauro, FR; Foa, R; Gattei, V; Gaidano, G; Boccadoro, M; Massaia, M; Coscia, M
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE
2017-01-01 Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, FR; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target
2018-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target
2018-01-01 Vitale C, Griggio V, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target
2020-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Targeting mevalonate pathway down-regulates ABCB1, reversing chemoresistance and immunoresistance in human cancer cells.
2012-01-01 Joanna Kopecka; Ivana Campia; Barbara Castella; Massimo Massaia; Chiara Riganti
Temozolomide epigenetically down-regulates Wnt3a-dependent signaling and P- glycoprotein in glioblastoma stem cells
2012-01-01 I. Campia; I.C. Salaroglio; J. Kopecka; M.L. Pinzòn; V. Caldera; D. Ghigo; A. Bosia; D. Schiffer; C. Riganti
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Cardiac glycosides as new modulators of cholesterol metabolism | 2012 | I. Campia; V. Sala; J. Kopecka; C. Leo; N. Mitro; C. Costamagna; D. Caruso; G. Pescarmona;T. Crepaldi; D. Ghigo; A. Bosia; C. Riganti | |
Cardiac glycosides modulate cholesterol metabolism via SREBP-2 and LXR activation | 2013 | I. Campia; V. Sala; J. Kopecka; C. Leo; N. Mitro; C. Costamagna; D. Caruso; G. Pescarmona;T. Crepaldi; D. Ghigo; A. Bosia; C. Riganti | |
Cardioactive glycosides induce the efflux of cholesterol by upregulating ABCA1 | 2012 | I. Campia; J. Kopecka ;G. Pescarmona; D. Ghigo ; C. Riganti | |
Digoxin and oubain increase the synthesis of cholesterol in human liver cells | 2011 | Joanna Kopecka; Ivana Campia; Amalia Bosia; Chiara Riganti | |
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target | 2016 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, Fr; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
Liposomal doxorubicin reverses drug-resistance by inhibiting P-glycoprotein in human cancer cells | 2010 | I. Campia; C. Riganti; C. Voena; J. Kopecka; E. Enrico; C. Costamagna; D. Ghigo; A. Bosia | |
Mechanisms of Vgamma9Vdelta2 T cell activation by soluble metabolites generated by the mevalonate pathway. | 2014 | P. Sciancalepore; B. Castella; J. Kopecka; I. Campia; G. Gelsomino; M. Foglietta; D. Ghigo; M. Boccadoro; C. Riganti; M. Massaia. | |
Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity | 2011 | M. Polimeni; C. Voena; J. Kopecka; C. Riganti; G. Pescarmona; A. Bosia; D. Ghigo | |
Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity | 2011 | Manuela Polimeni; Claudia Voena; Johanna Kopecka; Chiara Riganti; Gianpiero Pescarmona; Amalia Bosia; Dario Ghigo | |
Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase activity | 2011 | M. Polimeni; C. Voena; J. Kopecka; C. Riganti; G. Pescarmona; A. Bosia; D. Ghigo | |
Nitrooxy-doxorubicin: A New Weapon Against Multidrug Resistance. | 2013 | Joanna Kopecka; Chiara Riganti; Barbara Rolando; Ivana Campia; Konstantin Chegaev; Loretta Lazzarato; Antonella Federico; Roberta Fruttero; Dario Ghigo | |
Pleiotropic effects of liposomal nanoparticles on ABCB1 in cancer cells | 2012 | I. Campia ; J.Kopecka; M.L. Pinzon; D. Ghigo; C. Riganti | |
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET | 2018 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Salvetti, C; Bomben, R; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Omede, P; Bonello, L; Kodipad, AA; Laurenti, L; Del Poeta, G; Mauro, FR; Bernardi, R; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET | 2016 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Laurenti, L; Zallio, F; Marchetti, M; Ruggeri, M; Omede, P; Ferretti, A; Del Poeta, G; Mauro, FR; Foa, R; Gattei, V; Gaidano, G; Boccadoro, M; Massaia, M; Coscia, M | |
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE | 2017 | Griggio, V; Vitale, C; Todaro, M; Riganti, C; Kopecka, J; Dal Bo, M; Rossi, D; Pozzato, G; Marchetti, M; Ruggeri, M; Omede, P; Laurenti, L; Del Poeta, G; Mauro, FR; Gattei, V; Gaidano, G; Foa, R; Massaia, M; Boccadoro, M; Coscia, M | |
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target | 2018 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target | 2018 | Vitale C, Griggio V, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omede’ P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target | 2020 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
Targeting mevalonate pathway down-regulates ABCB1, reversing chemoresistance and immunoresistance in human cancer cells. | 2012 | Joanna Kopecka; Ivana Campia; Barbara Castella; Massimo Massaia; Chiara Riganti | |
Temozolomide epigenetically down-regulates Wnt3a-dependent signaling and P- glycoprotein in glioblastoma stem cells | 2012 | I. Campia; I.C. Salaroglio; J. Kopecka; M.L. Pinzòn; V. Caldera; D. Ghigo; A. Bosia; D. Schiffer; C. Riganti |